<div id="readability-page-1"><div>AFT Pharmaceuticals is targeting more than $300 million in revenue for financial year 2027 after delivering double-digit growth across all territories and record earnings for the year to 31 March 2026.The New Zealand-based pharmaceutical company lifted full-year operating revenue by 22% to $254.7m as its Australasian base continued to scale and international hubs began contributing more strongly.Operating profit reached $24.4m, ahead of the company’s $20m to $24m guidance range, while net profit after tax increased 24% to $14.1m.Australasia remained the core earnings and cash generation engine, with revenue increasing 16% to $210.5m including a 19% jump in Australian revenue as over-the-counter brands delivered broad-based strength and prescription medicines continued to gain traction.New Zealand revenue increased 11%, supported by momentum across allergy, dermatology, and eyecare, along with ongoing growth in hospital injectables and prescription medicines.International Hubs ScaleAFT now sells products in 87 countries, while its global distribution partnerships cover more than 100 countries, and the company’s international strategy is increasingly focused on building business hubs in markets with similar commercial and regulatory dynamics to its Australasian operations.International product sales and royalties increased 66% to $28.5m as customers returned to more normal buying patterns and the company continued scaling its offshore hubs, while Asia revenue rose 41% to $15.6m as trading normalised after one-off disruptions in FY25.The UK business is expected to break even in FY27, while the South African operation is also expected to contribute to earnings after integrating acquired products and adding staff across finance, logistics and regulatory affairs.AFT launched Combogesic IV in Canada during the year and has further launches planned after adding a chief executive officer, hospital key account managers, and a contract field force.In the US, Combogesic Rapid will be distributed through Mark Cuban’s CostPlus platform across all 50 states, while Hikma continues to distribute Combogesic IV.The company’s consumer products including Liposachets, Kiwisoothe, and Optisoothe, are available through Amazon, with additional channels being finalised for commercialisation in FY27.Licensing Activity BuildsLicensing income rose to $3.1m from $0.7m as AFT closed nine new agreements during FY26, with a significant number of additional agreements in negotiation.Several R&amp;D programs have moved from development toward revenue generation, giving AFT a broader pathway to monetise its proprietary intellectual property.AFT lifted total R&amp;D expenditure, including expensed and capitalised spend, to $18m from $15m in FY25, with plans to increase that investment to $25m in FY27 as it advances a larger portfolio that includes eight patented products and more than 24 off-patent injectables.Preparations are advancing for Maxigesic and Maxigesic IV studies in paediatric populations after US Food and Drug Administration approval of study plans, with the first site expected to start in June.Pipeline DevelopmentAFT has licensed its intravenous iron development project to Chengdu-based Grand Life Sciences Group under an arrangement that includes development and sales milestone payments.The company is preparing a large global Phase 3 trial of about 1,366 patients for the intravenous iron project.Work also continues across an antibiotic eye drop, a topical treatment for strawberry birthmarks, a topical treatment for keloid scars, a burning mouth treatment, and a novel injectable formulation opportunity.AFT expects to file regulatory dossiers for at least five Sinoject injectables before the end of FY27.FY27 Growth PathwayAFT expects FY27 growth to come from continued Australasian expansion, international launches, scaling hub contributions, regulatory milestones, and further licensing activity.Co-founder and managing director Dr Hartley Atkinson said the company remained focused on broadening its business while addressing unmet clinical needs, and on track to reach its $300 million revenue goal for FY27.“We are growing in our established markets and we are building a wider, more diversified AFT through disciplined international expansion, out-licensing the intellectual property from our R&amp;D programs, and further advancing our efforts to address unmet clinical needs,” he said.AFT believes its broader geographic and product base strengthened the resilience of the business as it entered another investment-led growth year.“We are well positioned to continue to grow by focusing on what we do best—identifying unmet clinical needs, in-licensing or developing medicines, and commercialising them to improve health globally,” Dr Atkinson added.</div></div>

AFT Pharmaceuticals aims for over $300 million in revenue by FY27 after reporting record earnings and 22% revenue growth to $254.7 million for FY26. Operating profit reached $24.4 million, exceeding guidance, while net profit rose 24% to $14.1 million. The company is expanding internationally, with significant growth in Asia and plans for new product launches. AFT is also increasing R&D investment to $25 million in FY27, focusing on unmet clinical needs and diversifying its product portfolio.

AFT Pharmaceuticals Targets Minimum $300m Revenue After Record Earnings